suramin has been researched along with Metastase in 22 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 9.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 7.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "Suramin-resistant DC-3F/SU 1,000 Chinese hamster fibrosarcoma cells were obtained by continuous exposure of parental DC-3F cells to increasing concentrations of suramin (1 mg/ml final concentration)." | 7.69 | Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. ( Larsen, AK; Lelièvre, S, 1994) |
| " We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity." | 6.77 | Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ( Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 5.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 3.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "Suramin-resistant DC-3F/SU 1,000 Chinese hamster fibrosarcoma cells were obtained by continuous exposure of parental DC-3F cells to increasing concentrations of suramin (1 mg/ml final concentration)." | 3.69 | Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. ( Larsen, AK; Lelièvre, S, 1994) |
| " We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity." | 2.77 | Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ( Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012) |
| " The suramin dosing nomogram used in phase I and II portions of the trial yielded the desired plasma level of 10-50 micromol/L from 4." | 2.73 | Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. ( Au, JJ; Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Ganapathi, R; George, S; Mekhail, T; Rini, BI; Roman, S; Shen, T; Wientjes, GM, 2008) |
| "Suramin was administered by intravenous infusions over 1 hour." | 2.69 | Phase II trial of suramin in patients with metastatic renal cell carcinoma. ( Dreicer, R; See, WA; Smith, DC; Williams, RD, 1999) |
| "Using this dosing schedule, suramin has limited activity against hormone-refractory metastatic prostate cancer." | 2.68 | Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. ( Belldegrun, A; deKernion, J; Graves, MC; Landaw, EM; McBride, JH; Mendoza, EF; Mondino, B; Rosen, PJ; Turcillo, P, 1996) |
| "Metastatic prostate cancer is a leading cause of cancer-related death in men." | 2.40 | Treatment options in androgen-independent prostate cancer. ( Lara, PN; Meyers, FJ, 1999) |
| " STATEMENT OF SIGNIFICANCE: The doxorubicin-loaded glycol chitosan-suramin nanoparticle (GCS-SM/DOX) is novel in the following aspects: SM acts as not only a gelator for the first time in the preparation of the nanoparticle but also an active pharmaceutical agent in the dosage form." | 1.51 | Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles. ( Cheng, B; Gao, F; Maissy, E; Xu, P, 2019) |
| "Exposure of 1E8 and 2B4 prostate cancer cells to ATP resulted in p38 activation in a concentration- and time-dependent manner." | 1.31 | [Activation of p38 and c-Jun NH2-terminal kinase mitogen-activated protein kinases in human prostate carcinoma cell lines with different metastatic potentials]. ( Fang, W; He, C; Heng, W; Li, H; Wu, B; You, J; Zheng, J, 2001) |
| "Micrometastases were identified in bone and liver 1 day after inoculation and grew to form established metastatic foci in all embryos." | 1.30 | A chick embryo model for metastatic human prostate cancer. ( Endo, Y; Imao, T; Kobayashi, T; Koshida, K; Namiki, M; Sasaki, T; Uchibayashi, T, 1998) |
| "A new therapeutic strategy for treating metastasis in hepatocellular carcinoma (HCC) has entailed the use of antiangiogenic agents such as suramin, BB-94 (Batimastat), TNP-470, and carboxyamido-triazole (CAI, a synthetic inhibitor of non-excitable calcium channels that reversibly inhibits angiogenesis)." | 1.30 | Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma. ( Bu, W; Li, XM; Qin, LX; Tang, ZY; Xia, JL, 1999) |
| "Suramin has long been used in the treatment of onchocerciasis and trypanosomiasis." | 1.29 | [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer]. ( Dieckmann, KP; Gollnick, H; Handke, A; Tebbe, B; Wichterich, K, 1994) |
| "In an experimental murine metastasis model host pretreatment protocol (HPP) was tested to abrogate lung colonization of tumor cells." | 1.28 | Experimental metastasis inhibition by pretreatment of the host. ( Ladányi, A; Lapis, K; Paku, S; Pápay, J; Szende, B; Timár, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (68.18) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, B | 1 |
| Gao, F | 1 |
| Maissy, E | 1 |
| Xu, P | 1 |
| Singla, AK | 1 |
| Bondareva, A | 1 |
| Jirik, FR | 1 |
| George, S | 1 |
| Dreicer, R | 2 |
| Au, JJ | 1 |
| Shen, T | 2 |
| Rini, BI | 1 |
| Roman, S | 1 |
| Cooney, MM | 1 |
| Mekhail, T | 1 |
| Elson, P | 1 |
| Wientjes, GM | 1 |
| Ganapathi, R | 1 |
| Bukowski, RM | 1 |
| Lustberg, MB | 1 |
| Pant, S | 1 |
| Ruppert, AS | 1 |
| Wei, Y | 1 |
| Chen, L | 1 |
| Brenner, L | 1 |
| Shiels, D | 1 |
| Jensen, RR | 1 |
| Berger, M | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Grever, M | 2 |
| Au, JL | 2 |
| Wientjes, MG | 2 |
| Shapiro, CL | 1 |
| Villalona-Calero, MA | 1 |
| Otterson, GA | 1 |
| Kanter, S | 1 |
| Young, D | 1 |
| Murgo, AJ | 1 |
| Fischer, B | 1 |
| DeHoff, C | 1 |
| Chen, D | 1 |
| Yeh, TK | 1 |
| Song, S | 1 |
| Zhang, P | 1 |
| He, JB | 1 |
| Ou, LW | 1 |
| Wang, XH | 1 |
| Lelièvre, S | 2 |
| Larsen, AK | 2 |
| Falcone, A | 1 |
| Pfanner, E | 1 |
| Cianci, C | 1 |
| Danesi, R | 1 |
| Brunetti, I | 1 |
| Del Tacca, M | 1 |
| Conte, PF | 1 |
| Marutsuka, K | 1 |
| Hasui, Y | 1 |
| Asada, Y | 1 |
| Naito, S | 1 |
| Osada, Y | 1 |
| Sumiyoshi, A | 1 |
| Wichterich, K | 1 |
| Tebbe, B | 1 |
| Handke, A | 1 |
| Dieckmann, KP | 1 |
| Gollnick, H | 1 |
| Tisdale, JF | 1 |
| Figg, WD | 1 |
| Reed, E | 1 |
| McCall, NA | 1 |
| Alkins, BR | 1 |
| Horne, MK | 1 |
| Rosen, PJ | 1 |
| Mendoza, EF | 1 |
| Landaw, EM | 1 |
| Mondino, B | 1 |
| Graves, MC | 1 |
| McBride, JH | 1 |
| Turcillo, P | 1 |
| deKernion, J | 1 |
| Belldegrun, A | 1 |
| Panvichian, R | 1 |
| Pienta, KJ | 1 |
| Konety, BR | 1 |
| Getzenberg, RH | 1 |
| Kobayashi, T | 1 |
| Koshida, K | 1 |
| Endo, Y | 1 |
| Imao, T | 1 |
| Uchibayashi, T | 1 |
| Sasaki, T | 1 |
| Namiki, M | 1 |
| Lawrence, JB | 1 |
| Conover, CA | 1 |
| Haddad, TC | 1 |
| Ingle, JN | 1 |
| Reid, JM | 1 |
| Ames, MM | 1 |
| Suman, VJ | 1 |
| Marks, RS | 1 |
| Erlichman, C | 1 |
| Hartmann, LC | 1 |
| Lara, PN | 1 |
| Meyers, FJ | 1 |
| Qin, LX | 1 |
| Tang, ZY | 1 |
| Li, XM | 1 |
| Bu, W | 1 |
| Xia, JL | 1 |
| Smith, DC | 1 |
| Williams, RD | 1 |
| See, WA | 1 |
| Li, H | 1 |
| Fang, W | 1 |
| He, C | 1 |
| You, J | 1 |
| Heng, W | 1 |
| Zheng, J | 1 |
| Wu, B | 1 |
| Lapis, K | 1 |
| Timár, J | 1 |
| Pápay, J | 1 |
| Paku, S | 1 |
| Szende, B | 1 |
| Ladányi, A | 1 |
3 reviews available for suramin and Metastase
| Article | Year |
|---|---|
The treatment of hormone refractory prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Estramu | 1996 |
Novel therapies for advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Bombesin; Diet; Enzyme Inhibitors; Epoprostenol; Genetic Therapy; Hu | 1997 |
Treatment options in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antibodies, Monoclonal; Antineoplastic Agents; Anti | 1999 |
8 trials available for suramin and Metastase
| Article | Year |
|---|---|
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 2008 |
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2012 |
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; D | 2003 |
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Neo | 1995 |
Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
Topics: Antineoplastic Agents; Humans; Immunoglobulin G; Male; Middle Aged; Neoplasm Metastasis; Platelet Ag | 1996 |
Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Half-Life; Humans; Male; Middle Aged; Neop | 1996 |
Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Hydrocortis | 1997 |
Phase II trial of suramin in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Infusions, Intrave | 1999 |
11 other studies available for suramin and Metastase
| Article | Year |
|---|---|
Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
Topics: Animals; Cell Line, Tumor; Chitosan; Doxorubicin; Female; Human Umbilical Vein Endothelial Cells; Hu | 2019 |
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Lin | 2014 |
[Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergi | 2006 |
[Acquisition of resistance to suramin in the cells of fibrosarcoma in Chinese hamsters accompanied by morphologic modification and increased metastatic capacity].
Topics: Animals; Cricetinae; Cricetulus; Drug Resistance; Fibrosarcoma; Neoplasm Metastasis; Neoplasms, Expe | 1994 |
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Topics: Animals; Carcinoma, Renal Cell; Cell Division; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Ne | 1995 |
Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential.
Topics: Animals; Cell Adhesion; Cell Count; Cell Division; Cricetinae; Cricetulus; Drug Resistance; Fibrosar | 1994 |
[Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Topics: Aged; Biopsy; Drug Eruptions; Drug Therapy, Combination; Humans; Infusions, Intravenous; Male; Middl | 1994 |
A chick embryo model for metastatic human prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Cell Division; Cell Transplantation; Chick Embryo; C | 1998 |
Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Division; Cyclohexanes; Liver Neoplasms, Experimental; Mice; Mi | 1999 |
[Activation of p38 and c-Jun NH2-terminal kinase mitogen-activated protein kinases in human prostate carcinoma cell lines with different metastatic potentials].
Topics: Adenosine Triphosphate; Cell Line, Tumor; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; | 2001 |
Experimental metastasis inhibition by pretreatment of the host.
Topics: Animals; Epoprostenol; Glycosaminoglycans; Lentinan; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; | 1990 |